Utama › Leukemia Mieloid Kronik › Maryland
Kajian klinikal Leukemia Mieloid Kronik di Maryland
6 kajian untuk Leukemia Mieloid Kronik sedang mencari peserta di lokasi di Maryland.
Bandar di Maryland
Teks kajian rasmi (Bahasa Inggeris)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1
Umur 18 hingga 120 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06904066Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- dan 10 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Mengambil pesertaFasa awal 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06398457Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1801, Baltimore
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06423911A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Johns Hopkins, Baltimore
- Nih/Niaid, Bethesda
- Nih/Nhlbi, Bethesda
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Maryland, Baltimore
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Nov 2025 · NCT04260022Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.